Zhang, Shirong <br/><br/>
Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective observational study.  [electronic resource] 

 -  Cancer communications (London, England)  05 2018 
 - 28 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Observational Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2523-3548 
<br/><br/><label>Standard No.: </label>10.1186/s40880-018-0303-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acrylamides--therapeutic use<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Aniline Compounds--therapeutic use<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Circulating Tumor DNA--blood<br/>ErbB Receptors--antagonists & inhibitors<br/>Female<br/>Humans<br/>Kaplan-Meier Estimate<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Mutation<br/>Prognosis<br/>Prospective Studies<br/>Protein Kinase Inhibitors--therapeutic use